Morbidity and mortality of the Russian population from acute respiratory viral infections, pneumonia and vaccination


Cite item

Full Text

Abstract

In order to assess the impact of influenza vaccination and pneumococcal infection (PI) were studied seasonal morbidity and mortality because of influenza, acute respiratory viral infections (ARVI) and pneumonia among the population of the Russian Federation during 2012-2016 timeframe.The methods. There were analyzed the data of Federal service for surveillance in consumer rights protection and human welfare (Rospotrebnadzor) on influenza vaccination and PI and ARVI morbidity (including influenza), diseases of the respiratory system (DRS). The information on mortality of the population of Russia because of these diseases received from official publications of the Federal State statistics service (Rosstat) and The Ministry of health of the Russian Federation (Ministry of Health of Russia) on the mortality rates of the population of Russia because of these illnesses. Results: the analysis revealed that compared to 2015, in 2016 the incidence rate of ARVI in total Russian population was increased to 5,7%. The incidence rate of influenza in 2016 reached 60,5 cases per 100 thousand of the total population and was higher than the 1,8 times than in 2015 (34,01 on 100 thousand people). The incidence rate of pneumonia in total population was increased by 24,0% in 2016 compared to 2015. According to Rosstat data, the increase of deaths because of influenza and ARVI was mainly in the first semester of 2016, which was associated with influenza epidemic. Mortality because of pneumonia dropped by 10,8% and from other DRS - by 6,9%, which might indicate on the improvement of the quality of medical care and prevention of DRS. Reduction in the mortality rate because of pneumonia also was due to significant influenza vaccination coverage and the increasing number of children and adults vaccinated against PI.

About the authors

T N Bilichenko

Research Institute of Pulmonology Federal medico-biological agency

Email: tbilichenko@yandex.ru
д.м.н., зав. лаб. клинической эпидемиологии Moscow

A G CHuchalin

Research Institute of Pulmonology Federal medico-biological agency

Email: chuchalin@inbox.ru
д.м.н., проф., акад. РАН, директор ФГБУ «НИИ пульмонологии» ФМБА России, зав. каф. госпитальной терапии педиатрического факультета Российского национального исследовательского медицинского университета им. Н.И. Пирогова Moscow

References

  1. О состоянии санитарно - эпидемиологического благополучия населения в Российской Федерации в 2016 году: Государственный доклад. - М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2017. - 220 с. Европейское региональное бюро ВОЗ: C. S. Brown, R. Andraghetti, J. Paget. Центры
  2. по контролю и профилактике заболеваний (CDC), США: J. Michalove, N. Dharan, J. Moran, J. A. Mott, A. Mounts. Рабочая группа экспертов - представителей государств - членов. Всемирная организация здравоохранения. Европейское руководство ВОЗ по эпиднадзору за гриппом среди людей. 2009. - 86 c.
  3. World health organization. Influenza virus infections in humans (February 2014). S 1- 2. https://doi.org/10.1016/b978-0-12-801238-3.00084-2 http://www.who.int/influenza/gisrs_laboratory/terminology_variant/en/index.html
  4. Coffin S.E, Zaoutis T.E, Rosenquist A.B, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community - acquired influenza. Pediatrics. 2007;119 (4):740-748. https://doi.org/10.1542/peds.2006-2679
  5. Finelli L, Fiore A, Dhara R, et al. Influenza - associated pediatric mortality in the United States: increase of Staphylococcus aureus coinfection. Pediatrics. 2009;122(4): 805-811. https://doi.org/10.1542/peds.2008-1336
  6. Bhat N, Wright J.G, Broder K.R, et al. Influenza - associated deaths among children in the United States, 2003-2004. N Engl J Med. 2005; 353(24): 2559-67. https://doi.org/10.1056/nejmoa051721
  7. Попова А.Ю., Ежлова Е.Б., Мельникова А.А., Фролова Н.В., Михеев В.Н., Рыжиков А.Б. О предварительных итогах эпидемического сезона 2015-2016 гг. по гриппу и ОРВИ в Российской Федерации. Consilium medicum. 2016;18(3):8-11.
  8. Yu H, Liao Q, Yuan Y, et al. Effectiveness of oseltamivir on disease progression and viral RNA shedding in patients with mild pandemic 2009 influenza A H1N1: opportunistic retrospective study of medical charts in China. British Medical Journal. 2010; 341(1): c4779.https://doi.org/ 10.1136/bmj.c4779
  9. Эффективная фармакотерапия. Медицинский форум. Сателлитный симпозиум ОАО «Валента Фарм». Грипп и ОРВИ: актуальная проблема современности. Эпидемиология и инфекции. 2016;(1):3-10.
  10. Зайцев А.А. Современный взгляд на режимы антибактериальной терапии внебольничных инфекций нижних дыхательных путей. РМЖ. 2016; (12): 786-790.
  11. Еженедельный эпидемиологический бюллетень. 23 ноября 2012 г. 2012;87(47):461-476. http://www.who.int/wer.
  12. Prosser L.A, O'Brien M.A, Molinari N.A, et al. Non-Traditional Settings for Influenza Vaccination of Adults. Pharmaco-Economics. 2008; 26(2): 163-178. https://doi.org/10.2165/00019053-200826020-00006

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).